These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 16026246)
41. A potent weapon in the battle against HIV: your own immune system. Proj Inf Perspect; 2002 Mar; (34):14-6. PubMed ID: 12038300 [TBL] [Abstract][Full Text] [Related]
42. Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines. Ferrantelli F; Cafaro A; Ensoli B Curr Opin Biotechnol; 2004 Dec; 15(6):543-56. PubMed ID: 15560981 [TBL] [Abstract][Full Text] [Related]
43. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Stamatatos L; Morris L; Burton DR; Mascola JR Nat Med; 2009 Aug; 15(8):866-70. PubMed ID: 19525964 [TBL] [Abstract][Full Text] [Related]
44. HIV vaccine development. Johnston MI Dev Biol (Basel); 2002; 110():57-63. PubMed ID: 12477307 [TBL] [Abstract][Full Text] [Related]
45. A global approach to HIV-1 vaccine development. Stephenson KE; Barouch DH Immunol Rev; 2013 Jul; 254(1):295-304. PubMed ID: 23772627 [TBL] [Abstract][Full Text] [Related]
47. Envelope glycoproteins of human immunodeficiency virus type 1: profound influences on immune functions. Chirmule N; Pahwa S Microbiol Rev; 1996 Jun; 60(2):386-406. PubMed ID: 8801439 [TBL] [Abstract][Full Text] [Related]
48. Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1. Xiang SH Curr HIV Res; 2013 Sep; 11(6):464-72. PubMed ID: 24033298 [TBL] [Abstract][Full Text] [Related]
49. FDA advisory committees meet January 26 on Salk HIV-1 immunogen. AIDS Treat News; 1995 Jan; (No 214):1-2. PubMed ID: 11362184 [TBL] [Abstract][Full Text] [Related]
50. Immune responses to HIV vaccines and potential impact on control of acute HIV-1 infection. McElrath MJ J Infect Dis; 2010 Oct; 202 Suppl 2(Suppl 2):S323-6. PubMed ID: 20846040 [TBL] [Abstract][Full Text] [Related]
51. Cytokine profiles in HIV type 1 disease and protection. Shearer GM; Clerici M AIDS Res Hum Retroviruses; 1998 Jun; 14 Suppl 2():S149-52. PubMed ID: 9672232 [No Abstract] [Full Text] [Related]
53. Rebuilding the immune system: promising new therapy uses the HIV virus itself to awaken the damaged immune system. Interview by Brian Coppedge and Dan Dawson. Moss R STEP Perspect; 1998; 98(2):13-6. PubMed ID: 11365540 [TBL] [Abstract][Full Text] [Related]
57. Immune enhancement trial begins. AIDS Patient Care STDS; 1996 Aug; 10(4):263. PubMed ID: 11361606 [No Abstract] [Full Text] [Related]
58. The design and testing of HIV prophylactic vaccines. Ada G AIDS Res Hum Retroviruses; 1992 May; 8(5):758-63. PubMed ID: 1515227 [No Abstract] [Full Text] [Related]
59. [AIDS vaccines and immunotherapy of infertility]. Bourinbaiar AS; Jirathitikal V; Hoffmann GW; Lu NQ Zhonghua Nan Ke Xue; 2005 Mar; 11(3):163-9. PubMed ID: 15804104 [TBL] [Abstract][Full Text] [Related]
60. Therapeutic vaccination: where are we now? Rosenberg ES AIDS Clin Care; 2003 Jan; 15(1):1-3. PubMed ID: 12685420 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]